Skip to main content

Advertisement

Table 8 The BW and BMI change in responder group and none-responder groups when subdivided according to different AAPs ( x - ± s )

From: Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

Two groups a AAP b N BW change (kg) P-value BMI change P-value
responder group clozapine 63 0.60 ± 3.94 0.012 0.21 ± 1.41 0.009
  risperidone 115 1.20 ± 3.71   0.46 ± 1.41  
  olanzapine 25 1.94 ± 4.47   0.76 ± 1.68  
  quetiapine 76 1.01 ± 3.41   0.37 ± 1.26  
  ziprasidone 32 -1.66 ± 4.78   -0.60 ± 1.74  
  aripiprazole 26 -0.67 ± 4.42   -0.19 ± 1.49  
none-responder group clozapine 7 -1.57 ± 2.30 0.917 -0.55 ± 0.80 0.834
  risperidone 11 -1.18 ± 1.99   -0.47 ± 0.79  
  olanzapine 5 -0.60 ± 1.82   -0.18 ± 0.62  
  quetiapine 8 -0.44 ± 2.87   -0.16 ± 1.07  
  ziprasidone 6 -1.5 ± 2.74   -0.56 ± 0.95  
  aripiprazole 3 -1.8 ± 3.69   -0.73 ± 1.42  
  1. a responder group and none-responder group
  2. b atypical antipsychotics